ArticleFrontiers in pharmacology2020
Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention.
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 2 syntheses or guidelines pooled it, 157 citations in OpenAlex.
- COVID-19 in comorbid chronic diseased patients, pregnant and lactating women: pathophysiology, available drug treatment, and the most suitable protocol regimen in each group.Inflammopharmacology · 2025Pooled it
- Association between Guillain-Barré syndrome and SARS-CoV-2 virus infection, including the impact of COVID-19 vaccination in the context of the development and general clinical characteristics of the disease.Journal of neurovirology · 2025Pooled it
- Association between COVID-19 infection, elevated C-reactive protein, and neuropsychiatric symptoms in individuals with metabolic and cardiovascular comorbidities.Metabolic brain disease · 2026Article
- Association of gender and main comorbidities with expression of lncRNAs and mRNAs in COVID-19 patients.Journal, genetic engineering & biotechnology · 2026Article
- Recent perspectives on macrophage memory: types, mechanisms, and characteristics in pulmonary diseases.Cell communication and signaling : CCS · 2026Review
- Case Report: Treatment of fulminant paraquat poisoning in a 32-week pregnant patient: a case report exploring the potential role of estrogen.Frontiers in pharmacology · 2026Article
- Ivermectin repurposing for COVID-19: pharmacological and bibliometric analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Caspases and brain-derived Neurotrophic Factor Levels and their Correlations with Psychiatric Symptoms in post-COVID-19.Neurotoxicity research · 2025Article
- Profile of Cytokines Associated with SARS-CoV2 Seropositivity in Multiple Sclerosis Patients and Its Persistence over Six Months.Journal of clinical medicine · 2025Article
- Garlic oil-loaded nanodisks for the amelioration of acute lung injury via modulation of the NF-κB and Keap1-Nrf2 axis.Frontiers in molecular biosciences · 2025Article
- Proteomic signatures of vaccine-induced and breakthrough infection-induced host responses to SARS-CoV-2.Vaccine · 2025Article
- Outcomes and inflammation changes in different types of immunocompromised patients with critically ill COVID-19 admitted to ICU: a national multicenter study.BMC pulmonary medicine · 2024Article
- Persistent ENT Manifestations in Individuals who Recovered from COVID-19: A Systematic Review.International archives of otorhinolaryngology · 2024Review
- The Link between Inflammation, Lipid Derivatives, and Microbiota Metabolites in COVID-19 Patients: Implications on Eating Behaviors and Nutritional Status.International journal of molecular sciences · 2024Review
- Frontiers and hotspots evolution in cytokine storm: A bibliometric analysis from 2004 to 2022.Heliyon · 2024Article
- First-episode psychiatric disorder risk from SARS-CoV-2 infection: A clinical analysis with Chinese psychiatric inpatients.Journal of biomedical research · 2024Article
- Review
- Review
- FGF18 alleviates sepsis-induced acute lung injury by inhibiting the NF-κB pathway.Respiratory research · 2024Article
- RNAseq of INOCA patients identifies innate, invariant, and acquired immune changes: potential autoimmune microvascular dysfunction.Frontiers in cardiovascular medicine · 2024Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the objective of linking early findings relating to the novel SARS-CoV-2 coronavirus with potentially informative findings from prior research literature and to promote investigation toward therapeutic response, a coherent cellular and molecular pathway is proposed for COVID-19. The pathway is consistent with a broad range of observed clinical features and biological markers and captures key mediators of pathophysiology. In this proposed pathway, membrane fusion and cytoplasmic entry of SARS-CoV-2 virus
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.